Stockscreener 앱 받기
8.17
1.11%
0.09
전일 마감가:
$8.08
열려 있는:
$8.1
하루 거래량:
579.85K
Relative Volume:
0.57
시가총액:
$505.26M
수익:
-
순이익/손실:
$-156.40M
주가수익비율:
-2.4909
EPS:
-3.2799
순현금흐름:
$-151.53M
1주 성능:
+2.64%
1개월 성능:
+2.90%
6개월 성능:
+12.53%
1년 성능:
+130.79%
1일 변동 폭
$7.80
$8.29
1주일 범위
$7.78
$8.6647
52주 변동 폭
$3.27
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
명칭
Kyverna Therapeutics Inc
전화
(510) 626-8331
주소
5980 HORTON STREET, EMERYVILLE
Compare KYTX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
8.17 | 497.84M | 0 | -156.40M | -151.53M | -3.2799 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-05-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-03 | 개시 | H.C. Wainwright | Neutral |
| 2024-03-04 | 개시 | JP Morgan | Overweight |
| 2024-03-04 | 개시 | Leerink Partners | Outperform |
| 2024-03-04 | 개시 | Morgan Stanley | Overweight |
| 2024-03-04 | 개시 | Wells Fargo | Overweight |
모두보기
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst - MarketBeat
Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake - Stock Titan
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX) - Seeking Alpha
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Kyverna Therapeutics (KYTX) Earnings Date and Reports 2026 $KYTX - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Releases Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Kyverna Therapeutics narrows Q2 losses, secures RMAT for miv-cel - scanx.trade
Kyverna Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kyverna Therapeutics Announces Q2 2026 Financial Results and Operational Update - Kalkine Media
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results - The Manila Times
KYTX: Q2 2026 net loss narrowed to $38.3M as miv-cel advanced toward commercialization - TradingView
Kyverna Therapeutics (KYTX) deepens pipeline with SPS BLA, H1 2026 loss narrows - Stock Titan
FDA designation puts Kyverna’s one-dose cell therapy in focus for progressive MS - Stock Titan
Renaissance Technologies LLC Grows Stock Holdings in Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Kyverna Therapeutics, Inc. expected to post a loss of 68 cents a shareEarnings Preview - TradingView
Kyverna Therapeutics Inc (KYTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Kyverna Therapeutics (KYTX) Institutional Ownership 2026 $KYTX - MarketBeat
Kyverna Therapeutics and ElevateBio Sign Commercial Manufacturing Agreement for Miv-Cel - BioPharm International
Kyverna Therapeutics (KYTX) Expected to Post Quarterly Earnings on Tuesday - MarketBeat
BlackRock (NYSE: BLK) discloses 5.1% beneficial stake in Kyverna Therapeutics (KYTX) - Stock Titan
ElevateBio inks deal to supply Kyverna’s CAR T-cell therapy for gMG - Myasthenia Gravis News
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel - BioInformant
Kyverna Therapeutics Inc (KYTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kyverna and ElevateBio collaborate on miv-cel - The Pharma Letter
William Blair Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating - Moomoo
Kyverna, ElevateBio Ink Manufacturing Agreement for Miv-Cel Supply - Contract Pharma
KYTX|Kyverna Therapeutics Inc|Price:7.890|Chg%:+0.480 - TradingKey
Kyverna Therapeutics, Inc. and Elevatebio, Inc. Enter into Commercial Manufacturing and Supply Agreement for Miv-Cel - marketscreener.com
Kyverna, ElevateBio sign manufacturing pact for miv-cel supply - Investing.com
Kyverna Therapeutics and ElevateBio Secure Scalable Manufacturing Agreement to Launch First CAR T-Cell Therapy for Autoimmune Diseases - Minichart
Kyverna Therapeutics Inc (KYTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kyverna Therapeutics Inc (KYTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kyverna Therapeutics And Elevatebio Enter Into Commercial Manufacturing And Supply Agreement For Miv-Cel - TradingView
Kyverna Therapeutics Inc (KYTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kyverna Therapeutics Inc (KYTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Kyverna Therapeutics Inc (KYTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kyverna Therapeutics Market Sentiment - Benzinga España
Kyverna Therapeutics Inc (KYTX) Cash Flow - TradingKey
KYTX|Kyverna Therapeutics Inc|Price:7.910|Chg%:+0.500 - TradingKey
KYTX|Kyverna Therapeutics Inc|Price:7.300|Chg%:-0.190 - TradingKey
Kyverna Therapeutics Inc (KYTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
KYTX|Kyverna Therapeutics Inc|Price:7.770|Chg%:+0.360 - TradingKey
Kyverna Therapeutics, Inc. Revenue Breakdown – NASDAQ:KYTX - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Wells Fargo Maintains Kyverna Therapeutics (KYTX) Overweight Recommendation - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kyverna Therapeutics (KYTX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Nadia Dac Net Worth (2026) - GuruFocus
Kyverna Therapeutics Inc (KYTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):